NSUN2 stimulates tumor progression via enhancing TIAM2 mRNA stability in pancreatic cancer

被引:0
|
作者
Guizhen Zhang
Liwen Liu
Jianhao Li
Yu Chen
Yun Wang
Yize Zhang
Zihui Dong
Wenhua Xue
Ranran Sun
Guangying Cui
机构
[1] The First Affiliated Hospital of Zhengzhou University,Department of Infectious Diseases
[2] The First Affiliated Hospital of Zhengzhou University,Gene Hospital of Henan Province, Precision Medicine Center
[3] Zhengzhou University,Academy of Medical Sciences
[4] Zhengzhou University,School of Basic Medical Sciences
[5] The First Affiliated Hospital of Zhengzhou University,Department of Pharmacy
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
NSUN2 is a nuclear RNA methyltransferase which catalyzes 5-methylcytosine (m5C), a posttranscriptional RNA modification. Aberrant m5C modification has been implicated in the development of multiple malignancies. However, its function in pancreatic cancer (PC) needs to be elucidated. Herein, we determined that NSUN2 was overexpressed in PC tissues and related to aggressive clinical features. Silence of NSUN2 by lentivirus weakened the capability of proliferation, migration and invasion of PC cells in vitro and inhibited the growth and metastasis of xenograft tumors in vivo. Contrarily, overexpression of NSUN2 stimulated PC growth and metastasis. Mechanistically, m5C-sequencing (m5C-seq) and RNA-sequencing (RNA-seq) were carried out to identify downstream targets of NSUN2 and results showed that loss of NSUN2 led to decreased m5C modification level concomitant with reduced TIAM2 mRNA expression. Further validation experiments proved that NSUN2 silence accelerated the decay of TIAM2 mRNA in a YBX1-dependent manner. Additionally, NSUN2 exerted its oncogenic function partially through enhancing TIAM2 transcription. More importantly, disruption of the NSUN2/TIAM2 axis repressed the malignant phenotype of PC cells through blocking epithelial-mesenchymal transition (EMT). Collectively, our study highlighted the critical function of NSUN2 in PC and provided novel mechanistic insights into NSUN2/TIAM2 axis as promising therapeutic targets against PC.
引用
收藏
相关论文
共 50 条
  • [31] CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA
    Yao, Bing
    Zhang, Qinglin
    Yang, Zhou
    An, Fangmei
    Nie, He
    Wang, Hui
    Yang, Cheng
    Sun, Jing
    Chen, Ke
    Zhou, Jingwan
    Bai, Bing
    Gu, Shouyong
    Zhao, Wei
    Zhan, Qiang
    MOLECULAR CANCER, 2022, 21 (01)
  • [32] NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer
    Chio, Iok In Christine
    Jafarnejad, Seyed Mehdi
    Ponz-Sarvise, Mariano
    Park, Youngkyu
    Rivera, Keith
    Palm, Wilhelm
    Ohlund, Daniel
    Hammell, Molly
    Crawford, Howard
    Schmidt, Edward
    Thompson, Craig
    Pappin, Darryl
    Sonenberg, Nahum
    Tuveson, David
    CANCER RESEARCH, 2017, 77
  • [33] NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
    Chio, Iok In Christine
    Jafarnejad, Seyed Mehdi
    Ponz-Sarvise, Mariano
    Park, Youngkyu
    Rivera, Keith
    Palm, Wilhelm
    Wilson, John
    Sangar, Vineet
    Hao, Yuan
    Oehlund, Daniel
    Wright, Kevin
    Filippini, Dea
    Lee, Eun Jung
    Da Silva, Brandon
    Schoepfer, Christina
    Wilkinson, John Erby
    Buscaglia, Jonathan M.
    DeNicola, Gina M.
    Tiriac, Herve
    Hammell, Molly
    Crawford, Howard C.
    Schmidt, Edward E.
    Thompson, Craig B.
    Pappin, Darryl J.
    Sonenberg, Nahum
    Tuveson, David A.
    CELL, 2016, 166 (04) : 963 - 976
  • [34] NSUN2-mediated m5C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression
    Zuo, Sipeng
    Li, Lin
    Wen, Xuyang
    Gu, Xiang
    Zhuang, Ai
    Li, Rui
    Ye, Fuxiang
    Ge, Shengfang
    Fan, Xianqun
    Fan, Jiayan
    Chai, Peiwei
    Lu, Linna
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (05):
  • [35] Roquin2 suppresses breast cancer progression by inhibiting tumor angiogenesis via selectively destabilizing proangiogenic factors mRNA
    Zhou, Meicen
    Lu, Wenbao
    Li, Bingwei
    Yuan, Xiaochen
    Liu, Mingming
    Han, Jianqun
    Liu, Xueting
    Li, Ailing
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (11): : 2884 - 2898
  • [36] LAMC2: New player in stemness and tumor progression in pancreatic cancer.
    Delle Cave, Donatella
    Iavazzo, Tea Teresa
    Mangini, Maria
    Andolfi, Gennaro
    Pirozzi, Teresa
    Di Domenico, Annalisa
    De Luca, Annachiara
    Lonardo, Enza
    CANCER RESEARCH, 2021, 81 (22) : 26 - 27
  • [37] An Inhibitory Ligand of Neuropilin 2 Blocks Pancreatic Cancer Progression and Impedes Tumor Angiogenesis
    Niclou, Benoit
    Li, Xiaoran
    Zessler, Astrid
    Jia, Amy
    Mahmood, Fabliha
    Briscoe, David M.
    Watnick, Randolph S.
    Adam, Rosalyn M.
    Bielenberg, Diane R.
    FASEB JOURNAL, 2019, 33
  • [38] EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6
    Patil, Shilpa
    Steuber, Benjamin
    Kopp, Waltraut
    Kari, Vijayalakshmi
    Urbach, Laura
    Wang, Xin
    Kueffer, Stefan
    Bohnenberger, Hanibal
    Spyropoulou, Dimitra
    Zhang, Zhe
    Versemann, Lennart
    Boesherz, Mark Sebastian
    Brunner, Marius
    Gaedcke, Jochen
    Stroebel, Philipp
    Zhang, Jin-San
    Neesse, Albrecht
    Ellenrieder, Volker
    Singh, Shiv K.
    Johnsen, Steven A.
    Hessmann, Elisabeth
    CANCER RESEARCH, 2020, 80 (21) : 4620 - 4632
  • [39] Pancreatic cancer progression via β2 adrenergic-neurotrophin feed forward loop
    Takahashi, Ryota
    Ijichi, Hideaki
    Koike, Kazuhiko
    CANCER SCIENCE, 2022, 113
  • [40] Long noncoding RNA DIAPH2-AS1 promotes neural invasion of gastric cancer via stabilizing NSUN2 to enhance the m5C modification of NTN1
    Li, Ying
    Xia, Yiwen
    Jiang, Tianlu
    Chen, Zetian
    Shen, Yikai
    Lin, Jie
    Xie, Li
    Gu, Chao
    Lv, Jialun
    Lu, Chen
    Zhang, Diancai
    Xu, Hao
    Yang, Li
    Xu, Zekuan
    Wang, Linjun
    CELL DEATH & DISEASE, 2023, 14 (04)